Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-30
2007-10-30
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000
Reexamination Certificate
active
10755854
ABSTRACT:
The present invention is directed to methods of identifying women at increased risk of having ovarian cancer. Identification is based upon the extent to which biological samples derived from the women exhibit elevated levels of eosinophil-derived neurotoxin (EDN).
REFERENCES:
patent: 5604106 (1997-02-01), Liotta et al.
patent: 5695761 (1997-12-01), Denhardt et al.
patent: 5712104 (1998-01-01), Yamamoto
patent: 5801004 (1998-09-01), Hudson et al.
patent: 5866119 (1999-02-01), Bandman et al.
patent: 5928883 (1999-07-01), Gleich et al.
patent: 6414219 (2002-07-01), Denhardt et al.
patent: 6675104 (2004-01-01), Paulse et al.
patent: 6686444 (2004-02-01), Ashkar
patent: 2002/0039753 (2002-04-01), Chai et al.
patent: 2002/0052308 (2002-05-01), Rosen et al.
patent: 2003/0087250 (2003-05-01), Monahan et al.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Brakora, et al., “Utility of Osteopontin as a Biomarker in Recurrent Epithelial Ovarian Cancer,”Gynoecologic Oncology 93:361-365 (2004).
Furger, et al., “The Functional and Clinical Roles of Osteopontin in Cancer and Metastasis,”Curr. Mol. Med. 1:621-632 (2001).
Schorge, et al., “Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer,”Clin. Cancer Res. 10:3474-3478 (2004).
Bast et al., “A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer,”N. Engl. J. Med. 309:883-887 (1983).
Berteau, et al., “Prostasin mRNA to Detect Prostate Cells in Blood of Cancer Patients,”,Clin. Chem. Lab. Med. 37:S119 (1999).
Chen, et al., “Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer,”Prostate 48:93-103 (2001).
Chen, et al., “Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and Is Transcriptionally Regulated by Promoter DNA Methylation,”Int. J. Cancer 97:323-329 (2002).
Cheung, et al., “Identify Metastasis-Associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor,”Cancer Res. 62:4711-4621 (2002).
Coolen, et al., “Elevation of Brain-Type Creatine Kinase in Serum from Patients with Carcinoma,”Cancer 44:1414-1418 (1979).
Cramer, et al., “Carotenoids, Antioxidants and Ovarian Cancer Risk in Pre- and Postmenopausal Women,”Int. J. Cancer 94:128-134 (2001).
Daly, et al., “The Search for Predictive Patterns in Ovarian Cancer: Proteomics Meets Bioinformatics,”Cancer Cell 1:111-112 (2002).
Denhardt, et al., “Osteopontin: A Protein with Diverse Functions,”FASEB J. 7:1475-1482 (1993).
DeRisi, et al., “Use of cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer,”Nature Genetics 14:457-460 (1996).
Fish, et al., “Changes in Serum Actue Phase Proteins in Ovarian Cancer Patients Receiving Cis-Diamminedichloro-platinum (CDDP) Infusion Therapy,”Clinical Biochem. 17:39-41 (1984).
Fish, et al., “Serum Haptoglobin and α1-Acid Glycoprotein as Indicators of the Effectiveness ofcis-Diamminedichloroplatinum (CDDP) in Ovarian Cancer Patients—a Preliminary Report,”Eur. J. Cancer Clin. Oncol. 20:625-630 (1984).
Giachelli, et al., “Molecular and Cellular Biology of Osteopontin,”Trends Cardiovasc. Med. 5:88-95 (1995).
Gingrich, et al., “Metastatic Prostate Cancer in a Transgenic Mouse,”Cancer Res. 56:4096-4102 (1996).
Harvey, et al., “Cancer Cells Release a Covalent Complex Containing Disulfide-Linker Domains from Urinary Plasminogen Activator, Neural Cell Adhesion Molecule, and Haptoglobin α and β Chains,”Arch. Biochem. Biopys. 345:289-298 (1997).
Heid, et al., “Real Time Quantitative PCR,”Genome Res. 6:986-994 (1996).
Hooper, et al., “Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors,”Cancer Res. 59:3199-3205 (1999).
Hooper, et al., “Localization, Expression and Genomic Structure of the Gene Encoding the Human Serine Protease Testisin,”Biochimica et Biophysica Acta 1492:63-71 (2000).
Kibel, et al., “Loss of Heterozygosity at 12P12-13 in Primary and Metastatic Prostate Adenocarcinoma,”J. Urol. 164:192-196 (2000).
Kiefer, et al., “The cDNA and Derived Amino Acid Sequence for Human Osteopontin,”Nuc. Ac. Res. 17:3306 (1989).
Kim, et al., “Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer,”JAMA 287:1671-1679 (2002).
Ko, et al., “Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients,”Chinese J. Microbiol. Immunol. 13:149-157 (1980).
Ko, et al., “Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients,”Chinese J. Microbiol. Immunol. 13:149-157 (1980) Abstract; Database Medline, Accession No. 81089629.
Kurtz, et al., “Serum Creatine Kinase BB Isoenzyme as a Diagnostic Aid in Occult Small Cell Lung Cancer,”Cancer 56:562-566 (1985).
Mills, et al., “Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics,”J. Natl. Cancer. Inst. 93:1437-1439 (2001).
Mok, et al., “Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology,”J. Natl. Cancer Inst. 93:1458-1464 (2001).
Mok, et al., “Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer,”Gynecologic Oncol. 52:247-252 (1994).
Mok, et al., “SPARC, an Extracellular Matrix Protein with Tumor-Suppressing Activity in Human Ovarian Epithelial Cells,”Oncogene 12:1895-1901 (1996).
Müeller-Pillasch, et al., “Cloning of a Gene Highly Overexpressed in Cancer Coding for a Novel KH-Domain Containing Protein,”Oncogene 14:2729-2733 (1997).
Oldberg, et al., “Cloning and Sequence Analysis of Rat Bone Sialoprotein (Osteopontin) cDNA Reveals an Arg-Gly-Asp Cell-Binding Sequence,”Proc. Natl. Acad. Sci. USA 83:8819-8823 (1986).
Oldberg, et al., “Identification of a Bone Sialoprotein Receptor in Osteosarcoma Cells,”J. Biol. Chem. 263:19433-19436 (1988).
Patarca, et al., “Differential Induction of Interferon γ Gene Expression after Activation of CD4+Cells by Conventional Antigen and Mls Superantigen,”Proc. Natl. Acad. Sci. USA 88:2736-2739 (1991).
Peng, et al., “Proteomics: The Move to Mixtures,”J. Mass Spectrom. 36:1083-1091 (2001).
Petricoin, et al., “Use of Proteomic Patterns in Serum to Identify Ovarian Cancer,”Lancet 359:572-577 (2002).
Piva, et al., “Interleukin-6 Differentially Stimulates Haptoglobin Production by Peritoneal and Endometriotic Cells in Vitro: A Model for Endometrial-Peritoneal Interaction in Endometriosis,”J. Clin. Endocrinol. Metab. 86:2553-2561 (2001).
Ren, et al., “Reduced Lysyl Oxidase Messenger RNA Levels in Experimental and Human Prostate Cancer,”Cancer Res. 58:1285-1290 (1998).
Schneider, et al., “Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer,”Clin. Cancer Res. 10:1588-1596 (2004).
Schriml, et al., “Tyramide Signal Amplification (TSA)-FISH Applied to Mapping PCR-Labeled Probes Less Than 1 kb in Size,”BioTechniques 27:608-613 (1999).
Schummer, et al., “Comparative Hybridization of an Array of 21 500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas,”Gene 238:375-385 (1999).
Senger, et al., “Elevated Expression of Secreted Phosphoprotein I (Osteopontin, 2ar) as a Consequence of Neoplastic Transformation,”Anticancer Res. 9:1291-1300 (1989).
Sharp, et al., “Tumor Cells Are the Source of Osteopontin and Bone Sialoprotein Expression in Human Breast Cancer,”Lab. Investing. 79:869-877 (1999).
Shindo, “Haptoglobin
Cramer Daniel W.
Mok Samuel C.
Ye Bin
Aeder Sean E.
Law Office of Michael A. Sanzo, LLC
Sanzo Michael A.
The Brigham and Women's Hospital, Inc.
Yu Misook
LandOfFree
Eosinophil-derived neurotoxin as a marker for ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Eosinophil-derived neurotoxin as a marker for ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eosinophil-derived neurotoxin as a marker for ovarian cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857649